Tests, treatment & safety
Which tests earn their place, where treatment claims outrun evidence, and when a clinician still needs to make the call.
Current evidence
Which routine checks have guideline support, where Lp(a) and ApoB fit, why broad panels create noise, and how age, symptoms, medication, and risk change the answer.
ChatGPT, medical benchmarks, diagnostic trials and mental-health chatbots. Where AI can help with health questions and where a clinician is still needed.
WHO, artemisinin, acupuncture, herbal-product adulteration and tai chi. Five claims that need separate evidence and separate safety decisions.
Botox treatment failure, sunscreen, fillers and skin screening. Why treatment can fail and which prevention claims are supported.
ApoB, Lp(a), coronary calcium and hidden cardiovascular risk in midlife. Which tests answer a clear question and which numbers need more context.
What human trials say about rapamycin, NAD precursors, creatine, metformin, urolithin A, and common biological-age claims.
What human research exists for BPC-157, what the FDA vote changed, how TB-500 differs from thymosin beta-4, and what online-product testing can establish.
Source editions
Stop paying for 100-marker panels. A doctor breaks down the handful of blood tests worth running, what to skip, and how to avoid false positives.
ChatGPT handles 80% of what your doctor does with your bloodwork. The 20% it misses can cost you a decade, and the nightly habit wrecking your sleep.
Is Chinese medicine ancient wisdom or elaborate theater? It is both. A doctor separates what survives the evidence from what can give you cancer.
Caring how you look is not vanity, it is biology. A surgeon ranks what actually works for your face, skin, hair, and teeth, and what to skip.
Looking healthy is not being healthy. Five heart tests, mostly left out of your checkup, that flag silent disease ten years before it strikes.
Rapamycin, NAD precursors, creatine, metformin, and the gap between a changed biomarker and a longer life.
BPC-157, weak human evidence, peptide marketing, product quality, and the choice not to inject an unapproved compound.